Correlation of Statistical Distributions of the Dimension of Yeast Cells Attached to the Substrate and Its Surface Electrical Potential

The ability of cells to adhere to substrates is an important factor for the effectiveness of biotechnologies and bioimplants. This research demonstrates that the statistical distribution of the sizes of the cells (Saccharomyces cerevisiae) attached to the substrate surface correlates with the statistical distribution of electrical potential on the substrate’s surface. Hypothetically, this behavior should be taken into consideration during the processing of surfaces when cell adhesion based on cell size is required.     

Effect of Heat Treatment on Microstructure and Selective Corrosion of LPBF-AlSi10Mg by Means of SKPFM and Exo-Electron Emission

The paper deals with the evolution of the microstructure of AlSi10Mg alloy obtained by laser powder bed fusion (LPBF), as a function of the post-processing heat treatment temperature. This was approached by complementary methods including FE-scanning electron microscopy, scanning Kelvin probe force microscopy and exo-electron emission techniques. The fast cooling rate of the LPBF process as compared to traditional casting produces a very fine microstructure with high mechanical properties and corrosion resistance. However, the LPBF-AlSi10Mg alloy can be susceptible to selective corrosion at the edge of the melt pools generated by the laser scan tracks. Post-process thermal treatments of the Al alloy induce a marked modification of the silicon network at melt pool edges, in particular at high temperature such as 400 °C. It was found that this is associated to a more homogeneous distribution of Volta potential. Analysis of exo-electron emission confirms the silicon diffusion during thermal treatment. The modification of the silicon network structure of the LPBF-AlSi10Mg during thermal treatment reduces the susceptibility to selective corrosion.     

Immunological targeting of the endothelial barrier antigen (EBA) in vivo leads to opening of the blood–brain barrier

The role of the endothelial barrier antigen (EBA) in the blood–brain barrier (BBB) of the rat is not fully understood. Pathological conditions which show BBB disruption and leakage of plasma proteins are associated with reduced EBA expression in brain endothelial cells (ECs). However, it is not known if the reduction in EBA is the primary event or is secondary to protein extravasation. We hypothesized that immunological targeting of EBA in vivo would lead to opening of the BBB. To test this hypothesis, a monoclonal antibody (anti-EBA) was intravenously injected in anaesthetized experimental rats. Control animals received intravenous injections of phosphate-buffered saline (PBS) or non-specific antibodies (anti-human cytokeratin, anti-Salmonella bacterial antigen, or anti-pan endothelial cell antigen). Two groups of rats were used, each included experimental and control animals. The first group was used for immunocytochemical detection of EBA in brain ECs and rat albumin in brain parenchyma. In the second group, the permeability of the BBB to horseradish peroxidase (HRP) was tested. Experimental animals, injected with anti-EBA antibody, showed extensive leakage of HRP and albumin in the grey and white matter of the brain. Immunocytochemistry of experimental brains showed that the intravenously injected anti-EBA became bound to ECs and was detected in tissue sections. Control animals did not show leakage of HRP or albumin, and EBA distribution was normal. This study demonstrated for the first time, that immunological ‘neutralisation’ of EBA leads to opening of the BBB, and provided direct evidence for the importance of EBA in maintaining the integrity of the BBB in the rat.     

A narrow time-window for access to the brain by exogenous protein after immunological targeting of a blood-brain barrier antigen

The endothelial barrier antigen (EBA) is a membrane protein expressed by endothelial cells of the rat blood-brain barrier (BBB). A previous short-term non-recovery study demonstrated that immunological targeting of EBA by intravenous administration of a monoclonal antibody (anti-EBA) led to acute opening of the BBB to exogenous and endogenous tracers. The aims of the present study were to determine whether opening of the BBB was reversible and compatible with survival, and whether a "therapeutic window" existed. A single intravenous injection of one of three doses (high, medium and low) of anti-EBA was used. Animals were allowed to survive for periods ranging from 17 min to 4 days. The tracer horseradish peroxidase (HRP) was administered intravenously 10 min before perfusion fixation, and its distribution was assessed in Vibratome sections of the brain and spinal cord. Leakage of HRP into the central nervous system was dose- and time-dependent. The medium dose produced incipient HRP leakage at 17 min and widespread pronounced leakage at 30 min. Progressive reduction in HRP permeability occurred from 45 min to 2 h, with barrier restoration by 3 h. At all subsequent time intervals (6 h-4 days) the BBB remained impermeable to HRP. The low and high doses produced less and greater HRP leakage, respectively, but restoration of the barrier still occurred at 3 h. The high dose, however, produced a number of deaths. Animals treated with an isotype control antibody showed no HRP leakage at comparable time intervals. The results indicated that (1) this model was compatible with survival, (2) opening of the BBB was monophasic and transient, occurring during a narrow "time-window", and (3) the barrier, once reconstituted, maintained its integrity.     

Immunological targeting of the endothelial barrier antigen (EBA) in vivo leads to opening of the blood-brain barrier

The role of the endothelial barrier antigen (EBA) in the blood-brain barrier (BBB) of the rat is not fully understood. Pathological conditions which show BBB disruption and leakage of plasma proteins are associated with reduced EBA expression in brain endothelial cells (ECs). However, it is not known if the reduction in EBA is the primary event or is secondary to protein extravasation. We hypothesized that immunological targeting of EBA in vivo would lead to opening of the BBB. To test this hypothesis, a monoclonal antibody (anti-EBA) was intravenously injected in anaesthetized experimental rats. Control animals received intravenous injections of phosphate-buffered saline (PBS) or non-specific antibodies (anti-human cytokeratin, anti-Salmonella bacterial antigen, or anti-pan endothelial cell antigen). Two groups of rats were used, each included experimental and control animals. The first group was used for immunocytochemical detection of EBA in brain ECs and rat albumin in brain parenchyma. In the second group, the permeability of the BBB to horseradish peroxidase (HRP) was tested. Experimental animals, injected with anti-EBA antibody, showed extensive leakage of HRP and albumin in the grey and white matter of the brain. Immunocytochemistry of experimental brains showed that the intravenously injected anti-EBA became bound to ECs and was detected in tissue sections. Control animals did not show leakage of HRP or albumin, and EBA distribution was normal. This study demonstrated for the first time, that immunological 'neutralisation' of EBA leads to opening of the BBB, and provided direct evidence for the importance of EBA in maintaining the integrity of the BBB in the rat.     

Scope for the “eye — hand” psychophysiological test in screening for cerebrovascular insufficiency

Conclusions 1. During performance of the eye hand PPT the reaction time to input signals at the same time contains information on the trend and level of noise and pulsation of the afferent and efferent pathways of the CNS in man.2. The eye — hand PPT is best performed for detecting subjects with possible CVI, and also to determine the precise degree of its severity.3. Introduction of the eye — hand PPT during mass prophylactic examinations is of economic importance because it enables the early discovery of abnormalities of the workers' health and optimal implementation of the tests in industry characterized by two or three shifts.Riga Medical Institute. Translated from Meditsinskaya Tekhnika, No. 2, pp. 5–7, March–April, 1991.